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ㅋ
The potential relevance of systemic and gastrointestinal immune activation in the pathophysiology and symptom generation in 
the irritable bowel syndrome (IBS) is supported by a number of observations. Infectious gastroenteritis is the strongest risk fac-
tor for the development of IBS and increased rates of IBS-like symptoms have been detected in patients with inflammatory 
bowel disease in remission or in celiac disease patients on a gluten free diet. The number of T cells and mast cells in the small 
and large intestine of patients with IBS is increased in a large proportion of patients with IBS over healthy controls. Mediators 
released by immune cells and likely from other non-immune competent cells impact on the function of enteric and sensory 
afferent nerves as well as on epithelial tight junctions controlling mucosal barrier of recipient animals, isolated human gut tis-
sues or cell culture systems. Antibodies against microbiota antigens (bacterial flagellin), and increased levels of cytokines have 
been detected systemically in the peripheral blood advocating the existence of abnormal host-microbial interactions and sys-
temic immune responses. Nonetheless, there is wide overlap of data obtained in healthy controls; in addition, the subsets of 
patients showing immune activation have yet to be clearly identified. Gender, age, geographic differences, genetic predis-
position, diet and differences in the intestinal microbiota likely play a role and further research has to be done to clarify their 
relevance as potential mechanisms in the described immune system dysregulation. Immune activation has stimulated interest 
for the potential identification of biomarkers useful for clinical and research purposes and the development of novel ther-
apeutic approaches. 
(J Neurogastroenterol Motil 2011;17:349-359)
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Introduction
The irritable bowel syndrome (IBS) is characterized by ab-
dominal pain/discomfort and changes in bowel habit which are 
not associated with organic causes. IBS represents one of the 
most common functional gastrointestinal (GI) disorders with an 
overall prevalence estimated around 10%-15% in Europe and the 
United States.
1 The pathophysiology of IBS is not completely 
understood, but believed to be the consequence of dysregulation 
of the brain-gut axis with both central and peripheral mechanism 
involved. Central mechanisms include anxiety, depression and 
somatisation while peripheral dysfunction is characterized by 
changes in gut motility and secretion as well as visceral hyper-
sensitivity.
2 Cellular and molecular abnormalities in mucosal en-
teroendocrine system as well as mucosal and systemic immune re-Giovanni Barbara, et al
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Figure 1. Putative biological factors 
involved in the pathophysiology of irri-
table bowel syndrome. CRF, cortico-
tropin releasing factor; SERT, serotonin 
reuptake transporter.
sponses have been postulated to participate in the brain-gut 
dysfunction.
3 A schematic representation of novel biological fac-
tors involved in IBS pathophysiology is provided in Figure 1.
Inflammation refers to the response of the immune system to 
injury and is characterized by the classical signs of redness 
(rubor), heat (calor), swelling (tumor) and pain (dolor) which 
have been originally described by the Roman encyclopedist 
Celsus
3 (25 BC-45 AD) in the famous ancient book De Medi-
cina. Rudolf Virchow in 1858 added to this definition the concept 
of functio laesa, reflecting functional impairment of the affected 
organs or tissues.
4 These pathological factors are determined by a 
cascade of biochemical events leading to the movement of leuko-
cytes (frequently granulocytes) from the blood into the tissue and 
the release of biological products (eg, proinflammatory cytokines) 
determining processes of tissue damage and subsequent healing. 
Classical examples of intestinal inflammatory diseases include in-
fectious gastroenteritis, caused by invasive pathogens such as 
Shigella, Salmonella and Clostridium difficile, idiopathic chronic in-
flammatory bowel diseases (IBD) including Crohn’s disease and 
ulcerative colitis, radiation enteropathy or acute diverticulitis. 
Clearly, the typical aspects of overt inflammation or mucosal ar-
chitecture distortion seen in these disorders are absent in patients 
with IBS. However, the application of quantitative assessment 
and the use of molecular biology has revealed the presence of 
mild activation of the immune system both locally (ie, intestinal 
mucosa) or systemically (ie, plasma, serum and peripheral blood 
mononuclear cells). Yet, conflicting results have been reported, 
probably reflecting the large overlap of data with healthy controls 
and the wide heterogeneity and protean symptom manifestations 
of the IBS population. The argument is whether these mild im-
mune abnormalities represent epiphenomena or are of relevance 
for the aberrant bowel function and symptom manifestation. 
Importantly, recent studies have shown that mucosal or luminal 
mediators obtained from patients with IBS, but not controls, 
evoked abnormal functional responses in enteric and sensory 
nerves and disrupted intestinal barrier integrity of recipient labo-
ratory animals, isolated rodent
5-7 or human tissues
8 or cell cul-
ture.
9 Most of these effects were ascribed to molecules of immune 
origin. A schematic figure representing this translational ap-
proach is provided in Figure 2. These results taken in con-
junction with data showing correlations with symptoms and ini-
tial evidence of some beneficial effects of immunomodulatory 
agents
10 support a contributing role of the immune system in the 
pathogenesis of at least a large subgroup of patients with IBS.
In the following review, we report on the rapidly evolving 
field on the potential pathogenetic role of the immune system in 
patients with IBS as well as clinical and therapeutic implications 
of these findings.
The Clinical Scenarios Linking Immune 
Activation to Irritable Bowel Syndrome
The implication of intestinal immune activation in the patho-
genesis of IBS is supported by at least 2 key clinical observations, 
namely: (1) the development of IBS symptoms in subjects in-
volved in an episode of acute infectious gastroenteritis (the so 
called post-infectious IBS) and (2) the reported higher preva-
lence of IBS-like symptoms in patients with IBD in remission, Immune Function and IBS
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Figure 2. Schematic representation of translational approach to assess the impact of mucosal bioactive factors on sensory afferents, enteric nerves and
epithelial permeability. (A) Mucosal biopsies are taken from the mucosa of descending colon. (B) Mucosal spontaneous release of bioactive factors is
obtained, collected and stored. (C) Laboratory animals and surgical resection specimens of colon are used as recipient for the assessment of the impact
of isolated mediators. (D) Readout of visceral sensitivity, sensory nerve discharge, enteric nervous system function and mucosal permeability can be 
assessed in the presence or absence of specific pharmacologic antagonists/inhibitors to identify specific molecules involved. IBS, irritable bowel 
syndrome; ENS, enteric nervous system. Adapted from Cenac et al,
5 Barbara et al,
6 Buhner et al
8 and Piche et al.
9
microscopic colitis or celiac disease on a gluten free diet.
Post-Infectious Irritable Bowel Syndrome
Following a bout of infectious gastroenteritis, a small but sig-
nificant proportion of subjects go on to develop post-infectious 
IBS, dyspepsia or both (for review, see reference
11). A recent sys-
tematic review and meta-analysis identified that the pooled in-
cidence for IBS development after infectious gastroenteritis was 
about 10% (95% CI, 9.40-85.6).
12 Recent studies focused on a 
waterborne outbreak of gastroenteritis involving around half of 
the population of the small town of Walkerton in Canada. 
Residents of this community developed gastroenteritis as a con-
sequence of accidental contamination of the municipal water sup-
ply with Escherichia coli O157:H7 and Campylobacter jejuni. Two 
years later, 36% of those infected developed IBS. Similarly to the 
previous smaller sample size reports, risk factors for the develop-
ment of IBS symptoms included: female gender and the severity 
of the initial illness, (ie, weight loss, bloody diarrhea and long du-
ration of the infectious episode).
13,14 Previous work also demon-
strated the importance of psychological co-morbidity for the de-
velopment of post-infectious IBS.
15 The mechanisms underlying 
the persistence of symptoms remain poorly defined, but may in-
clude genetic factors, particularly related polymorphisms for 
genes involved in pro-inflammatory cytokine production (IL-6) 
and host-bacteria interactions (one of the bacterial recognition re-
ceptor, toll-like receptor 9) as well as molecules involved in the 
control of mucosal permeability (tight junctions).
16 Intestinal tis-
sue analysis identified the persistence of low-grade immune acti-
vation and enteroendocrine abnormalities. Spiller et al
17 showed 
increased numbers of intraepithelial lymphocytes, lamina propria 
T cells, calprotectin-positive macrophages and enteroendocrine 
cells which failed to decline in patients who develop post-in-
fectious IBS. Others have reported an increased number of mast 
cells in the terminal ileum,
18 while the number of these cells was 
normal in the rectum.
18,19
Irritable Bowel Syndrome-Like Symptoms 
in Patients With Inflammatory Bowel 
Diseases, Microscopic Colitis and Celiac 
Disease
IBS-like symptoms develop in about 50% of patients with 
microscopic colitis
20 and in 33%-57% of patients with ulcerative 
colitis or Crohn’s disease in remission.
21,22 These figures are sub-
stantially higher than the expected prevalence of IBS in the gen-
eral population and support the assumption that human low- 
grade mucosal inflammation could play a role on IBS symptom Giovanni Barbara, et al
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development. Interestingly, IBS-like symptoms in patients with 
IBD were significantly associated to the presence of psychological 
impairment and poor quality of life.
22,23 IBD is thought to result 
from inappropriate and ongoing activation of the mucosal im-
mune system driven by the intestinal microbiota. This aberrant 
response is facilitated by defects in both the barrier function of the 
intestinal epithelium and the mucosal immune system, which are 
likely influenced by genetic factors.
24 As our understanding 
evolves, it appears that many of these mechanisms are common to 
IBS and IBD although obvious quantitative-qualitative differ-
ences exist.
Similarly to IBD and microscopic colitis a high rate of 
IBS-like symptoms has been reported in patients with celiac dis-
ease living on a gluten free diet and after apparent resolution of 
mucosal damage and immune activation.
25,26 Whether a mild im-
mune activity in the mucosa and minimal changes in mucosal 
permeability are involved in the symptom persistence in these pa-
tients remains to be determined.
Systemic Immune Activation
Although IBS is characterized mainly by changes in bowel 
function, it shows many systemic features with frequent associa-
tion with psychological factors and co-morbidities with other GI 
(eg, functional dyspepsia) and extra-intestinal (eg, migraine, fi-
bromyalgia and interstitial cystitis) disorders.
27 Interestingly, 
mild infiltration of immune cells interacting with tissue in-
nervation has been described in the gut of patients with IBS as 
well as in some co-morbid conditions, including fibromyalgia,
28 
interstitial cystitis
29 and vulvar vestibulitis.
30
Subsets of patients with IBS show evidence of abnormal sys-
temic immune responses. In particular, a high proportion of pa-
tients displays an increased frequency of circulating cytotoxic 
CD8+ T cells expressing the gut homing integrin α4β7.
31 This 
well correlates with increased CD8+ T cells in the lamina prop-
ria and epithelium (intraepithelial lymphocytes) in patients with 
nonspecific and post-infectious IBS.
17,31-33 On the other hand, 
circulating CD4+ T cells seem to play no role since CD4+/ 
CD25+ regulatory T cells, which are known to be involved in 
suppressing inflammation, showed similar frequencies in IBS pa-
tients and controls.
34 The role of B cells and relative antibody 
production is controversial. An increased IgG+ B cell frequency 
has been reported in the blood of IBS patients,
35 which is in keep-
ing with the detection of circulating antibodies to bacterial flag-
ellin in IBS.
36 However, 2 studies reported that the numbers of 
mucosal B cells were unchanged in IBS patients vs controls.
32,37
Overall, the currently available data show increased levels of 
plasma/serum pro-inflammatory cytokines, including IL-1β, 
TNF-α, IL-6 and IL-8,
38,39 as well as higher release of similar 
patterns of cytokines from resting or stimulated peripheral blood 
mononuclear cells
40,41 in patients with IBS compared with healthy 
controls. Interesting data suggest that, besides proinflammatory 
cytokines, the systemic immune response may be driven by the 
release of Th2 cytokines, including IL-5 and IL-13 by polycloni-
cally stimulated blood T cells.
42 Th2 cytokines are involved in the 
stimulation of certain types of immune activation seen in allergic 
disorders such as asthma and atopic dermatitis and in parasitic 
infections.
Mucosal Immune Activation
The intestinal mucosa generally contains an increased num-
ber of immunocytes (mainly T cells and mast cells) along with al-
teration of gene expression of several components of the host mu-
cosal immune response to microbial pathogens.
43 Most studies 
reported increased infiltration of immune cells in the rectum
24 
and colon,
33 however, increased mast cell numbers
44,45 and intra-
epithelial lymphocytes
46 have also been detected in the ileum and 
duodenum, indicating the involvement of the small bowel. The 
intestinal mucosa produces also higher amounts of different me-
diators including proteases, histamine and prostaglandins, but 
likely not proinflammatory cytokines.
5,6,47,48 Comparative studies 
demonstrated that the magnitude of the immune infiltrate de-
tected in patients with IBS was markedly lower than that of active 
or quiescent ulcerative colitis.
32 However, the number of immune 
cells of IBS overlapped with that detectable in patients with mi-
croscopic colitis,
32 even if only a minority (1.5%) of patients ful-
filling Rome II criteria for IBS satisfied stringent criteria for mi-
croscopic colitis.
49
Mast cells, a key component of the innate immune system, 
are considered as sentinels strategically located at the interface be-
tween the host and the external environment. They can be acti-
vated by both the cross-link of IgE (allergic reactions type I) and 
non classical pathways including neuro-hormonal stimulation, 
particularly following stressful experience.
50 Upon activation, 
mast cells release a number of biologically active substances con-
tained in their granules, including histamine, serotonin and 
proteases. They can also release cytokines and membrane-derived 
arachidonic acid metabolites including prostaglandins and 
leukotriens.
50 There are several reports indicating that mast cell Immune Function and IBS
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counts are increased in the mucosa of both the large and small in-
testine in patients with IBS compared with controls.
32,37,45,51,52 
Ultrastructural studies showed increased features of activation of 
mast cells including higher proportion of cells with of clearing of 
single granules and labyrintic arrays.
47 This well correlates with 
higher release of the mast cell mediators histamine and pro-
teases.
6,47 Although histamine is specific for mast cells, increased 
production of proteases in the intestine may also originate from 
luminal and mucosal associated bacteria.
53 There is also an in-
filtration of cells of the adaptive immunity in IBS as demon-
strated by significantly higher counts of mucosal CD3+, CD4+ 
and CD8+ T cells compared with controls.
17,31-33,51 In addition, 
increased mucosal staining of the CD25 marker in the colonic 
mucosa suggests increased activation of T cells.
33 We found that 
roughly 50% of IBS patients showed an increased mucosa cellu-
larity suggesting the potential relevance of immune mechanisms 
only in a subset of patients.
32 However, the exact subgroups of 
patients showing these abnormalities remain ill defined. In our 
previous studies we found that mast cell increase was gender 
dependent. Compared to male IBS, female patients showed 
greater numbers of mast cells but lower numbers of CD3+ and 
CD8+ T cells.
32,47 These findings are in keeping with the knowl-
edge that the immune system differs between males and fe-
males.
54 The correlation of immune cell infiltration with patients’ 
bowel habit is controversial. A similar degree of mast cell infiltra-
tion was found in patients with predominant diarrhea or con-
stipation
32,47,51,52 while other studies have reported that immune 
cell counts were higher in patients with diarrhea.
44,45
Although a number of studies support the evidence of im-
mune activation in different sites along the GI tract in IBS, neg-
ative studies have also been published. For example, Cenac et al,
5 
failed to find increased number of mast cells in the rectum or as-
cending colon of patients with IBS as compared with healthy 
controls. Similarly, MacSharry et al
48 found that the levels of 
IL-1β, TNF-α and IL-6 measured in biopsy samples were com-
parable between patients and controls. The mentioned wide over-
lap with healthy controls, different methodological approaches 
across studies (eg, patient and healthy control selection, labo-
ratory methods and bowel preparation) and geographical differ-
ences may, at least in part, explain these apparently contradictory 
results. Site of sampling may also be considered as another fac-
tor in the interpretation of the negative studies. For example, 
O’Sullivan et al,
37 detected increased mast cells numbers in the 
cecum, irrespective of bowel habit, but not in other sites of sam-
pling along the colon or rectum.
Impact of Immune Activation on 
Gastrointestinal Sensorimotor Function 
and Intestinal Barrier
There are possible implications of immune system activation 
in the pathophysiology of IBS (Fig. 1). As reported in detail 
above, mast cells have been the focus of several studies evaluating 
putative mechanisms underlying IBS symptom generation.
47 
Mast cells are found in close proximity to nerves supplying the 
gut mucosa. This close spatial association is considered a key fea-
ture underlying the crosstalk between the immune and nervous 
system in the gut.
55 We and others have previously demonstrated 
that mast cells of IBS patients were located in closer vicinity to 
mucosal innervation, suggesting that mediators released by mast 
cells, including tryptase and histamine, have an increased poten-
tial to affect neural function.
47,56
The biological significance of mast cells and mediators re-
leased from the intestinal mucosa of patients with IBS for gut 
sensory-motor function has been assessed. Mediators have been 
isolated and transferred to whole or isolated tissues from labo-
ratory animals (eg, rat and mouse) or to surgically removed in-
testinal samples (Fig. 2).
5,6,8,57 Mucosal mediators of IBS pati-
ents, but not controls, evoked increased activation of sensory pain 
pathways when applied to isolated intestinal preparations from 
the rat.
6 Supernatants from colonic biopsies caused somatic and 
visceral hyperalgesia and allodynia when applied to mice.
5 In ad-
dition, supernatants obtained from colonic biopsies of patients 
with IBS evoked abnormally high activation of human enteric 
neruons, via histamine, serotonin and protease-dependent mech-
anisms, suggesting the implication of mast cells as well as other 
potential cell components.
8 Serine proteases released by mast 
cells, and possibly also from intestinal bacteria, have been studied 
in further detail. Proteases are markedly increased in the mucosa 
of patients with IBS
5,47,58 and may act as signaling pain molecules 
via the activation of protease activated receptors (PAR) located 
on intestinal nerves conveying pain stimuli to the brain.
5,47,59 
Trypsin and tryptase nociceptive effects evoked in mice were re-
duced by serine protease inhibitors as well as by antagonist of the 
receptor PAR2 or in PAR2-deficient mice.
5 These studies estab-
lished that released proteases stimulate sensory neurons and gen-
erate pain sensitivity through the activation of PAR2.
Another particularly active field of investigation relates to the 
potential effect of biological products released by the intestinal 
mucosa and/or luminal factors on the integrity of the intestinal Giovanni Barbara, et al
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barrier. This interest has been generated by previous evidence of 
increased intestinal permeability in patients with post-infectious 
and diarrhea-predominant IBS.
9,13,17 T r a n s f e r  o f  f e c a l  s u p e r -
natants from patients with diarrhea-predominant IBS evoked in-
creased mucosal permeability in mice
7 and mucosal factors ob-
tained from IBS evoked epithelial barrier dysfunction and tight 
junction disruption in isolated epithelial monolayers.
9 The effect 
of fecal supernatants on epithelial barrier were absent in mice 
lacking PAR-2.
7 These results suggest that mucosal or luminal 
mediators impact negatively on mucosal barrier by increasing epi-
thelial permeability through a protease, PAR-2-dependent path-
way and open new avenues for therapeutic intervention.
What Causes Immune Activation in 
Irritable Bowel Syndrome?
The causes of intestinal immune cell activation in IBS pa-
tients remain unclear. A number of mechanisms has been postu-
lated, including undetected food allergies,
60 stress,
61 previous in-
fections (post-infectious IBS),
11 abnormal microbiota,
62 bile acid 
malabsorption
63 and increased intestinal permeability.
9
There is considerable evidence linking central nervous sys-
tem mechanisms with symptom perception in patients with IBS. 
Accordingly, IBS symptoms are sometimes exacerbated by stress 
and can be associated with psychological co-morbidities such as 
anxiety, depression, hypochondiasis and phobic disorders.
64 The 
mechanisms through which the brain affects bowel physiology in 
patients with IBS are not completely understood, but may involve 
bidirectional interactions in the brain-gut-axis through changes 
in neurotransmitter release affecting motor, endocrine, autonom-
ic and immune function.
65 Corticotropin-releasing factor (CRF) 
is a key mediator of stress response in the brain-gut-axis in IBS 
(Fig. 1).
61,66 Activation of CRF-receptor 1 in the periphery caus-
es a proinflammatory response and pro-nociceptive responses. 
CRF and related receptors represent an interesting potential 
mechanism of brain-gut axis dysfunction in IBS an exciting po-
tential therapeutic target in these patients which deserve further 
attention.
67
The contribution of genetic polymorphysms to immune acti-
vation remains elusive and yet controversial. Data indicate that 
larger proportions of IBS patients show the high producing het-
erozygous TNF-α G/A polymorphism at position-308.
68 Signifi-
cantly reduced frequencies of the high producer genotype for 
IL-10 have been also described, suggesting a specific genetic pre-
disposition to inflammation.
69 However, the latter finding has not 
been confirmed in a more recent study.
68
As previously stated enteric infection is now a recognized risk 
factor for the development of post-infectious IBS. It has been 
postulated that these patients are unable to efficiently suppress 
the initial immune response with persistence of mildly increased 
mucosal infiltration of T cells.
15,17,18
The epithelial lining could be a target of the immune activa-
tion, with proteases contributing to reduced expression of mole-
cules involved in tight junction function (ie, zonula occludens-1) 
and consequent increased epithelial permeability.
9 On the other 
hand, increased permeability could participate to ongoing in-
testinal immune stimulation by uncontrolled exposure of the lam-
ina propria to an abnormal antigenic load.
70
Several lines of evidence suggest the contribution of intestinal 
microbiota in the pathophysiology of IBS including: (1) presence 
of antibodies against flagellin (a component of indigenous bac-
teria inhabiting the human gut), in patients’ subgroups
36; (2) im-
provement of symptoms following modulation of gut micro-
biota
71 with probiotics
72 and non-absorbable antibiotics
73; and (3) 
microbiota instability over time as well as significant differences 
in bacterial composition (mainly reduced lactobacilli and bifido-
bacteria with elevated aerobe to anaerobe ratios).
74-76 Given the 
recognized role of intestinal microbiota in the stimulation of the 
immune system,
77 these observations are of potential importance 
for the identification of pathways of intestinal and systemic im-
mune activation in IBS patients. This field is rapidly growing and 
takes now advantage of high throughput culture-independent 
molecular techniques. These methods eliminate the bias of miss-
ing the vast majority of intestinal microbiota. Results so far pub-
lished hold promises for the identification of a potential factor in-
volved in the abnormal stimulation of mucosal immune system.
Implications of Immune Activation for 
Symptom Perception
Several correlations between immune activation and IBS 
symptoms have been described, although remain incompletely 
clarified (Table). Some studies were underpowered by inclusion 
of limited number of patients and controls. In addition, correla-
tion coefficients were sometimes weak. However, it is interesting 
to note that positive correlations have been found between the 
number of colonic mast cells and abdominal pain
51 or bloating
32 
and between blood T cells and bowel habit dissatisfaction as well 
as global IBS symptoms.
78 The correlation of blood TNF-α with 
anxiety and mucosal mast cells with fatigue and depression sug-Immune Function and IBS
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Table. Correlation of Immune Activation With Irritable Bowel Syndrome Symptoms
 Patients (n)  Immune factor  Site Symptoms  Correlation  P-value Author 
23 Mast cells  Colon Abdominal pain  r = 0.47 P = 0.004 Akbar et al,
51 2008
44 Abdominal pain  None P ＞ 0.05 Barbara et al,
47 2004
48 Addominal pain  None P ＞ 0.05 Cremon et al,
32 2009
48 Abdominal bloating  r = 0.39 P = 0.022 Cremon et al,
32 2009
20 Mast cells  Jejunum Global GI symptoms  None  P ＞ 0.05 Guilarte,
44 2008 
44 Mast cells close to nerves  Colon Abdominal pain  r = 0.75  P = 0.001 Barbara,
47 2004 
50 Mast cells  Colon Fatigue  r = 0.64 P = 0.0001 Piche et al,
52 2008
Depression r  =  0.29 P = 0.03
74 T cells  Blood Bowel habit dissatisfaction  r = 0.30 P = 0.02 Ohman et al,
78 2009
Global IBS symptoms  r = 0.29  P = 0.02 Ohman et al,
78 2009 
74 B cells  Blood IBS symptoms  None  P ＞ 0.05 Ohman et al,
78 2009 
55 TNF-α release Serum Anxiety r = 0.59  P = 0.001 Liebregts et al,
40 2007
38 Proteases Feces  IBS  symptoms, diarrhea  None  P ＞ 0.05 Róka et al,
58 2007
51 Mucosal permeability Colon Abdominal pain r = 0.65 P = 0.01 Piche et al,
9 2009
GI, gastrointestinal; IBS, irritable bowel syndrome.
gests the relevance of psychological factors and the brain-gut axis 
in IBS. A strong significant correlation has been repeatedly found 
between increased mucosal permeability and abdominal pain,
9,79 
further supporting the hypothesis that a barrier defect is of key 
importance for the activation of mucosal immune responses and 
related stimulation of pain pathways. So far, the strongest associa-
tion reported relates to the number of mast cells found in close 
proximity to nerves with the frequency and severity of abdominal 
pain (r = 0.70 and 0.75).
47 These findings suggest the con-
tribution of the interactions of mucosal immune cells (ie, mast 
cells) with the neural network conveying information to the cen-
tral nervous system to abdominal pain perception.
Are Immune Factors Useful Biomarkers in 
Clinical Practice?
The identification of measurable, objective biological factors 
associated with IBS has generated considerable interest for the 
“discovery” of a reliable biomarker useful to overcome the limi-
tations of current symptom-based definitions in daily clinical 
practice, expand the knowledge of pathophysiology and facilitate 
the development of novel therapeutic interventions (for review, 
see references
80,81). Patients could also benefit from the identi-
fication of biomarkers to shake themselves off the label of “appre-
hensive,” otherwise healthy individuals with “an imaginary dis-
ease.” In addition, the possibility to measure biological mediators 
non-invasively (blood or fecal samples) has increased the appeal 
for biomarker discovery. Unfortunately, the immunological bio-
markers so far described show wide overlap with controls and in-
creased levels of pro-inflammatory cytokines have been detected 
also in patients with other functional GI disorders
42 or depres-
sion,
82 suggesting poor sensitivity and specificity.
80 On the other 
hand more invasive studies (eg, mast cells in proximity to nerve 
endings) may well correlate with symptoms but are difficult to 
perform, requiring cumbersome laboratory techniques, confining 
their value for research rather than clinical practice. Despite these 
limitations, the biological basis of symptom generation are being 
recognized in subgroups of patients with IBS paving the way for 
the identification of one, or more likely more than one, IBS 
biomarkers.
80
Therapeutic Implications
Conceptually, drugs inhibiting intestinal immune activation 
would provide an excellent proof for implication of immune 
mechanisms in IBS pathophysiology and symptom generation. In 
a small controlled trial Dunlop et al
83 tested the efficacy of oral 
prednisolone (30 mg/day) in patients with post-infectious IBS. 
Mucosal T cell counts decreased but this was not accompanied 
by symptomatic improvement of abdominal pain, diarrhea, fre-
quency or urgency.
83 Although these results may be viewed as a 
proof against the role of immune factors in symptom perception 
in patients with post-infectious IBS, the short duration of treat-
ment and a relatively small steroid dosage could represent poten-
tial limiting factors responsible for negative results. Whether a 
longer course of topical steroids could be more effective remains 
undetermined.
The use of chromones (mast cell stabilizers) in patients with Giovanni Barbara, et al
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IBS dates back to the ‘80s when a significant 40% symptomatic 
improvement over control was shown in a small cohort of IBS 
patients.
84 Other studies have provided evidence of improvement 
of abdominal pain and diarrhea in IBS over placebo
85 or elimi-
nation diet.
86 There are limitation of these studies related to the 
small sample size and the suboptimal trial design (eg, uncon-
trolled, unblinded design in some studies, crossover design, short 
term treatment duration or lack of follow-up). Novel trials of 
chromones are now under way and we await the results with 
interest.
In a proof-of-concept randomized, double-blind, placebo- 
controlled trial, we have recently evaluated the potential of 5-ami-
nosalicylic acid (mesalazine, 800 mg 3 times daily for 8 weeks) on 
intestinal immune cells and symptom perception in patients with 
IBS.
87 Compared with placebo, mesalazine significantly reduced 
mucosal immune cells with a marked suppressive effect on mast 
cells. Although the study was underpowered for the assessment of 
symptoms, we detected a significantly improvement of general 
well being and abdominal pain, although the latter did not reach 
statistical significance. These data are in agreement with other 
preliminary uncontrolled trials showing that mesalazine reduced 
pain and stool frequency and improved stool consistency in pa-
tients with post-infectious IBS or non-specific IBS.
88-90 Further 
larger studies are now required to test the efficacy of mesalazine 
on IBS symptoms.
The intestinal microbiota has been the target of different ap-
proaches including prebiotics, probiotics, synbiotics, non-absorb-
able and systemic antibiotics.
62 A number of mechanisms of ac-
tion make probiotics very attractive for the treatment of IBS. 
These include their beneficial effects on gut inflammation, in-
testinal barrier function and inhibitory effects on visceral hyper-
sensitivity. In general, numerous randomized, placebo-controlled 
trials have demonstrated improvement in flatulence, abdominal 
distension and composite IBS symptoms scores (for review, see 
references
62,91). However, to date there is only limited evidence 
suggesting that probiotics exert their beneficial effects by modu-
lating immune function in patients with IBS. In a well designed 
s t u d y ,  O ’ M a h o n y  e t  a l
92 showed that Bifidobacterium infantis 
35624, but not Lactobacillus salivarius, was able to reduce sys-
temic pro-inflammatory cytokine profile along with symptom 
improvement.
Conclusions and Future Perspectives
Several lines of evidence support the implication of a systemic 
or intestinal immune activation in IBS patients. Initial data ob-
tained in pilot studies suggest that the immune system could be 
an interesting and novel target. However, further studies in larg-
er samples are now needed to clarify the importance of these mild 
abnormalities for symptom generation and the role of anti-in-
flammatory therapies in patients with IBS.
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